	Pat	ient Label
Moving <i>Forward</i>	Patient Name:	
after Breast Cancer	Date of Birth:	CR#:
	Diagnosis Date:	

Follow-Up Recommendations Breast Cancer Patients on Tamoxifen

Follow-up	heains	at the en	d of prima	rv therany	(surgerv	/ chemotherapy	/ radiation)
i oliow-up	Degins		ι οι ριππαι	yuididhy	(Suryery	/ chemounerapy	raulation

 Tamoxifen 20mg daily for 5-10 years based on c 	Years 1 – 3	Years 4 – 5	Years 6+		
 Primary Care Visits (Family Physician / Nurse F - History and focused examination: breast(s), chest w nodes, lungs, bones, abdomen, CNS, arm for lymph Assess patient's tolerance to Tamoxifen and menop post- menopausal until one year of amenorrhea and blood work). Tamoxifen can inaccurately suggest m Regular gynecological follow up – assess for irregular associated with Tamoxifen 	Every 3-6 months	Every 6 months	Annually		
Mammogram **Not required for patients who have - Begin one year after the mammogram that led to months after radiation treatment - More frequently if recommended by radiologist - Performed at a diagnostic mammography facility, - If life expectancy is 5 years or less, then mammogra - In the reconstructed breast, NO routine imaging if a	Annually	Annually	Annually		
Non-hormonal methods of contraception	Pregnancy is contraindicated while taking Tamoxifen, Suggest condoms/ spermacide jelly, non-hormonal IUD. If patient wants to pursue pregnancy, please refer back to the oncologist for a discussion.				
X-Rays, CT- US- MRI- Bone-PET Scans, tumour markers, CBC, Biochemistry		NOT performed if asymptomatic			
Tamoxifen Duration/ Oncologist Consultation	If the patient has been on tamoxifen for a total of 5 years, please refer the patient to CCMB for a discussion regarding switching to an Aromatase Inhibitor or extending Tamoxifen therapy to 10 years. Fax a referral to CCMB at 204-786-0621.				
Tamoxifen Issues and Suggested Management					

Medication Interactions: Please review any antidepressants the patient is taking as some interfere with the efficacy of Tamoxifen.

Hot flashes: Try morning dosing; add venlafaxine, gabapentin/pregabalin or clonidine.

Vaginal dryness: Use vaginal moisturizers & lubricants, use of intravaginal estrogens is relatively contraindicated.

Increased vaginal discharge: Increased discharge can be common but if symptomatic test to rule out infection.

Risk of uterine cancer: Risk of 0.2% - 0.3% per year for post-menopausal women. ALL post-menopausal bleeding requires transvaginal US and/or endometrial biopsy and referral to gynecology if concerned.

Risk of venous thromboembolism: Risk is 0.2% per year. Encourage smoking cessation, be vigilant for VTE symptoms.

Vision Changes: Risk of early cataract formation is very low; however Manitoba Health covers the cost of basic eve exams for women on Tamoxifen every one to two years.

Physician / Nurse Practitioner Visits

- Challenges in recovery? Refer to Breast & Gyne Cancer Centre of Hope at 204-787-2970. 0
- Abnormal symptoms or signs should be investigated with exam, lab and imaging. 0
- Encourage patient to see MD/NP regarding any worrisome symptoms without waiting for their next regular appointment. 0
- Patients can consult with the Breast Cancer Patient & Family Educator for assistance with managing Tamoxifen related issues at 204-0 787-4130 or toll-free 1-866-561-1026.

Common Symptoms of Recurrence or Metastases Abdominal symptoms

Bone pain 0

0

0

- Cough, dyspnea
- Breast changes/lumps
- Mastectomy scar changes 0 Frequent headache 0
- Fatigue 0
- Anorexia or weight loss 0
- Personality or vision changes 0

What to do if concerned about cancer recurrence

- New breast abnormality? Order diagnostic mammogram AND refer back to original surgeon urgently, even if mammogram is read as normal. In 0 reconstructed breast? Refer to plastic surgeon, consider ultrasound or MRI.
- Evidence of distant metastases? Please initiate investigations and fax a referral to the CCMB Referral Office at 204-786-0621 and indicate if 0 patient is highly symptomatic. Patient will be contacted within 2-3 working days.

Surveillance Recommendations & Checklist 2016